SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon gains on launching GLP-1 peptide, Liraglutide in Netherlands

15 Dec 2025 Evaluate

Biocon is currently trading at Rs. 391.30, up by 4.65 points or 1.20% from its previous closing of Rs. 386.65 on the BSE.

The scrip opened at Rs. 387.45 and has touched a high and low of Rs. 391.40 and Rs. 383.70 respectively. So far 60966 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.

Last one week high and low of the scrip stood at Rs. 395.50 and Rs. 375.90 respectively. The current market cap of the company is Rs. 52021.26 crore.

The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.71% and 16.83% respectively.

Biocon has launched its GLP-1 peptide, Liraglutide, for diabetes (gVictoza) and obesity (gSaxenda), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.

The launch follows the approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year and will mark the first country in the European Union where the Company will directly launch Liraglutide under its own brand.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

358.20 7.65 (2.18%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×